About 15 million Americans are on a GLP-1 right now
One in eight US adults has tried a GLP-1 receptor agonist. Roughly 6% — around 15 million people — are currently taking one, according to a KFF Health Tracking Poll from late 2024. That number has almost certainly grown since.
To put that in context: more Americans now take semaglutide or tirzepatide than take blood pressure medication from the ACE inhibitor class. GLP-1s went from a niche diabetes drug category in 2019 to one of the most-prescribed drug classes in the country by 2025.
TL;DR
- 15M+ US adults currently on a GLP-1 (KFF survey, 2024)
- Medicare Part D GLP-1 spending: $27.5B gross in 2024, up from $5.5B in 2019
- 21.8 million Medicare GLP-1 claims in 2024 (4x the 2019 level)
- 2 million Medicare enrollees on Ozempic alone in 2024
- Tirzepatide (Mounjaro/Zepbound) overtook semaglutide as the #1 prescribed GLP-1 by December 2025
- 40% of GLP-1 users take it only for weight loss, not diabetes
Where these numbers come from
Three data sources tell different parts of the story. None of them gives the full picture alone.
| Source | What it measures | Coverage | Latest data |
|---|---|---|---|
| KFF Health Tracking Poll | Self-reported GLP-1 use | All US adults | Nov 2024 |
| KFF Medicare Part D analysis | Claims-based GLP-1 use | Medicare only (50M people) | 2024 calendar year |
| Truveta Research | EHR prescriptions across health systems | Multi-payer sample | Jan 2019 - Dec 2025 |
The KFF survey gives the population estimate (15M+). The Medicare data gives exact dollar figures. Truveta shows the trajectory over time. Nobody has combined all three into a single coherent picture — which is what this post does.
Medicare: $27.5 billion and climbing
KFF published their Medicare GLP-1 analysis on January 30, 2026, using complete 2024 claims data. The headline numbers are staggering.
| Metric | 2019 | 2024 | Change |
|---|---|---|---|
| Gross Part D spending on GLP-1s | $5.5B | $27.5B | +400% |
| Net spending (after ~50% rebates) | ~$2.8B | ~$14B | +400% |
| Total GLP-1 claims | 4.8M | 21.8M | +354% |
| Ozempic enrollees | <150K | 2M | +1,233% |
| Mounjaro enrollees | 0 (not yet approved) | ~1M | N/A |
That $27.5 billion is gross spending before manufacturer rebates. Net spending (what Medicare actually pays after Novo Nordisk and Lilly kick back ~50%) is closer to $14 billion. Still massive. GLP-1s now consume roughly 12% of total Part D drug spending.
The per-patient math: at list prices around $900-1,300 per month, a single GLP-1 prescription costs Medicare $10,800-15,600 per year per patient. Multiply by 3+ million Medicare GLP-1 users, and you get the $27.5B figure.
Beyond Medicare: the numbers nobody tracks well
Here's the gap in public data. Medicare covers about 50 million people. The US has 330 million. What about everyone else?
Commercial insurance: No single public dataset tracks commercial GLP-1 prescriptions nationally. IQVIA and Symphony Health have this data, but it's behind paywalls. Based on the KFF survey (6% of all adults, ~15M people) minus the ~3M Medicare GLP-1 users, roughly 12 million non-Medicare Americans are on these drugs. Most are commercially insured adults aged 35-64.
Cash pay and compounded: Before the FDA cracked down on compounding pharmacies in early 2026, an estimated 2-3 million people were getting compounded semaglutide or tirzepatide. These prescriptions never show up in insurance claims data. At peak (mid-2025), compounded products represented about 15% of all GLP-1 prescriptions.
Medicaid: State Medicaid programs have been slow to cover GLP-1s for obesity (most still only cover them for type 2 diabetes). Medicaid GLP-1 spending data is fragmented across 50 state programs with no unified public reporting.
The real total is probably 16-18 million current users in mid-2026, accounting for growth since the KFF survey.
The prescribing trajectory
Truveta Research tracked GLP-1 prescriptions across their network of health systems from January 2019 through December 2025. Their data shows the inflection point clearly.
Key findings from the Truveta analysis (published January 20, 2026):
- 2,185,238 unique patients received at least one GLP-1 prescription in their network (2019-2025)
- 11.19 million total prescriptions written
- GLP-1s grew from under 1% of all prescriptions in 2019 to over 7% by December 2025
- Tirzepatide (Mounjaro/Zepbound) became the single most-prescribed anti-diabetes AND anti-obesity medication by Q4 2025
The growth curve is not slowing down. Each quarter in 2025 set a new record for GLP-1 prescriptions written.
Who's taking them — and why
The KFF survey breaks down GLP-1 users by reason:
| Reason for taking | Share of users |
|---|---|
| Type 2 diabetes only | 35% |
| Weight loss only | 40% |
| Both diabetes and weight loss | 20% |
| Other (cardiovascular, PCOS, etc.) | 5% |
Forty percent of GLP-1 users are taking these drugs purely for weight management, without a diabetes diagnosis. That's about 6 million Americans on a $1,000/month injection for weight loss.
The demographic skew: GLP-1 use is highest among adults aged 45-64, those with household income above $75K, and those with commercial insurance. The "typical" GLP-1 user in 2026 is a middle-aged, commercially insured adult using the drug for weight loss with partial or full insurance coverage.
The persistence problem nobody talks about
Starting a GLP-1 is common. Staying on one is not.
Clinical trial data shows approximately two-thirds of weight lost on semaglutide is regained within one year of stopping. But real-world persistence rates are far worse than trial retention:
- About 30-40% of new GLP-1 starts discontinue within 6 months (primarily due to cost, side effects, or supply issues)
- Medicare data shows roughly 60% of GLP-1 users in 2023 were still filling prescriptions 12 months later
- The compounding market existed partly because patients who lost insurance coverage or hit coverage gaps still wanted to stay on the drug at a lower price
This means the "15 million current users" number is actually a snapshot of a much larger revolving door. Over 25 million Americans have tried a GLP-1 at some point. The active user count is lower because many cycled off.
For the healthcare system, this creates a long-term cost question: are GLP-1s a lifetime medication for most users? If yes, the spending projections get much larger than current figures suggest.
Ozempic vs. Mounjaro vs. Wegovy: market share
The GLP-1 market is not monolithic. Three products dominate, each targeting a different segment.
| Product | Molecule | Approved for | Monthly list price | Medicare share (2024) |
|---|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | ~$935 | Largest by enrollment |
| Wegovy | Semaglutide | Chronic weight management | ~$1,349 | Limited (weight loss coverage restrictions) |
| Mounjaro | Tirzepatide | Type 2 diabetes | ~$1,023 | Fastest-growing |
| Zepbound | Tirzepatide | Chronic weight management | ~$1,059 | Newest (approved Nov 2023) |
Ozempic still has the largest user base by name recognition and Medicare enrollment. But tirzepatide products (Mounjaro + Zepbound combined) overtook semaglutide products as the most-prescribed GLP-1 class by December 2025, per Truveta data.
The brand vs. generic timeline matters here. Novo Nordisk's semaglutide patents begin expiring in 2026-2027. First generic semaglutide could reach market by late 2027 or 2028. Tirzepatide patents run longer. This means semaglutide's price will eventually drop — but tirzepatide's won't, at least not for several more years.
What the Inflation Reduction Act changes
Medicare selected Ozempic/Wegovy (semaglutide) for price negotiation in the second round (2025 selection, prices effective 2027). This is the single largest policy event for GLP-1 economics.
What we know:
- The negotiated Medicare price will apply starting January 2027
- Current gross cost to Medicare: roughly $900-1,300/month per patient
- Expected negotiated price: estimates range from 40-60% discount (based on first-round drug negotiations achieving 38-79% reductions)
- If Medicare's net semaglutide cost drops 50%, that's ~$7B/year in savings on semaglutide alone
For the 2+ million Medicare enrollees on Ozempic, out-of-pocket costs should drop significantly in 2027. The negotiated price also creates a benchmark that commercial insurers may reference.
State-level variation
GLP-1 prescribing is not uniform across the country. Medicare data (via the Part D Prescriber file) shows significant state-level variation.
States with highest GLP-1 prescribing rates per capita tend to be:
- Southern states with high obesity and diabetes prevalence (Mississippi, Alabama, Louisiana, West Virginia)
- States with more generous Medicaid GLP-1 coverage
States with lowest per-capita rates:
- States where Medicaid excludes obesity-indication coverage
- States with younger average populations and lower diabetes prevalence
The irony: states with the highest medical need for GLP-1s often have the largest insurance coverage gaps for weight-loss indications.
What happens next
Three forces will reshape GLP-1 prescribing data in 2026-2027:
1. IRA price negotiation (2027). Lower Medicare prices could expand access for price-sensitive patients currently avoiding the drugs.
2. Compounding crackdown. The 2-3 million people on compounded GLP-1s need to transition to brand products or stop. Some will absorb into the brand market. Others will drop off entirely. This shift will show up as a bump in brand prescriptions and a corresponding jump in insurance claims data.
3. New indications. Semaglutide's cardiovascular risk reduction indication (SELECT trial) and potential MASH (liver disease) approval expand the eligible patient population beyond diabetes and obesity. IQVIA estimates the addressable population could double if cardiovascular indications drive broader prescribing.
Conservative projection: 20-25 million active GLP-1 users in the US by end of 2027.
FAQ
How many people take Ozempic specifically? About 2 million Medicare enrollees were on Ozempic in 2024 (KFF, January 2026). Including commercial and cash-pay patients, total US Ozempic users are likely 4-5 million.
Are GLP-1 prescriptions still increasing in 2026? Yes. Every available data source shows continued growth through 2025 and into 2026. The Truveta EHR data showed GLP-1s exceeding 7% of all prescriptions by December 2025, with no plateau.
How much does a GLP-1 cost per month? List prices: Ozempic ~$935, Wegovy ~$1,349, Mounjaro ~$1,023, Zepbound ~$1,059. With commercial insurance copays range from $25-$150. Without insurance, expect full list price or compounded alternatives (where still legally available).
What percentage of GLP-1 users take them for weight loss vs. diabetes? About 40% take GLP-1s purely for weight loss, 35% for diabetes only, 20% for both, and 5% for other conditions (KFF survey, 2024).
Will generic Ozempic be available soon? Semaglutide patents begin expiring in 2026-2027. Generic versions could reach the US market by late 2027 or 2028, depending on FDA approval timelines and patent litigation outcomes.
How many people stop taking GLP-1 drugs? Real-world data shows 30-40% discontinue within 6 months. About 60% are still filling prescriptions at 12 months. Cost, side effects, and supply issues are the main reasons people stop.
Does Medicare cover GLP-1s for weight loss? Medicare Part D covers GLP-1s for type 2 diabetes (Ozempic, Mounjaro). Coverage for obesity/weight management indications (Wegovy, Zepbound) is limited and varies by plan. The TREAT Act, if passed, would mandate Medicare obesity drug coverage.
How does GLP-1 spending compare to other drug classes? GLP-1s are now the single most expensive drug class in Medicare Part D, surpassing blood thinners (Eliquis/Xarelto) and oncology drugs. At $27.5B gross spending in 2024, they consume about 12% of total Part D spending.
Where can I find this data myself? Key public sources: KFF Medicare Part D analysis (kff.org), CMS Part D Spending by Drug file (data.cms.gov), Truveta Research publications (truveta.com), and the openFDA NDC directory for drug identification.
Data from KFF "Recent Trends in GLP-1 Use and Spending in Medicare" (January 30, 2026), KFF Health Tracking Poll via CNN (May 2024), and Truveta Research "GLP-1 RA prescription trends" (January 20, 2026). Medicare spending figures are gross (before manufacturer rebates). Last verified August 2026.
Want this data delivered programmatically? The MyfitByte API tracks GLP-1 prescribing volumes, FDA enforcement actions, and adverse event reports across all US-approved medications. See our Medicare drug spending analysis and GLP-1 recall tracker for related data.
Published on 2026-08-24 · 11 min read
← Back to all articles